| # Gate 1 Post-Mortem β Subspace validity FAIL |
|
|
| **Date:** 2026-06-18 |
| **Gate:** 1 (subspace validity) β the load-bearing, "most likely failure point" per IMPLEMENTATION_SPEC. |
| **Outcome:** FAIL. Neither label-free lesion-subspace construction localizes LIDC nodules |
| better than a CLS-attention saliency comparator; both barely beat random. |
| |
| ## What was tested |
| |
| Token-level lesion-membership AUROC on held-out LIDC val patches (916,496 patches over 4,676 |
| slices: 2,338 lesion-bearing + 2,338 sampled negatives; lesion prevalence 0.48%). Patch masks |
| were materialized fresh from TCIA DICOM-SEG (z-ordered, image+mask written together β see |
| `jobs/materialize_lidc_masks_job.py`), because the original eryon manifest's per-slice nodule |
| positions were found to be misaligned with the authoritative SEG under every slice ordering. |
|
|
| Scores compared, all from the frozen MedDINOv3 ViT-B/16 features: |
| - Construction A: density / kNN-sparse (mean k-NN distance to the 2.1M-token CT bank). |
| - Construction B: normal-manifold residual (β(I β UUα΅)zβ, U = top-64 PCA of the bank). |
| - Comparator: CLS-to-patch attention from the last block (exact, captured from SDPA). |
| - Comparator: random. |
|
|
| ## Result |
|
|
| | Scorer | AUROC | 95% CI (DeLong) | |
| |---|---|---| |
| | Attention-saliency | **0.767** | [0.761, 0.773] | |
| | Construction A (density) | 0.565 | [0.558, 0.572] | |
| | Construction B (residual) | 0.551 | [0.544, 0.558] | |
| | Random | 0.511 | [0.503, 0.520] | |
|
|
| DeLong paired differences: A β attention = β0.202 [β0.209, β0.194]; B β attention = |
| β0.216 [β0.223, β0.208]. Both exclude 0 in the **wrong** direction (p β 0). |
|
|
| Dice@q0.9 vs mask (weak, but > random proxy ~0.005): A 0.079 (>3-patch) / 0.023 (1β3 patch); |
| B 0.067 / 0.020. |
|
|
| ## Interpretation |
|
|
| The central, explicitly-flagged assumption β *the label-free lesion subspace L(x) localizes |
| lesions without labels in MedDINOv3 feature space* β does not hold as constructed. Both the |
| density-sparsity prior (Construction A) and the normal-manifold-residual prior (Construction B) |
| carry only weak lesion signal (AUROC ~0.55β0.56), and are decisively beaten by the simplest |
| supervised-free saliency the spec named as the comparator. |
|
|
| The attention comparator scoring 0.767 on the **same** patches confirms the evaluation is |
| sound (masks, patch rasterization, and alignment are correct) β so this is a true property of |
| the constructions, not an eval artifact. The likely mechanism: in CT, "rare / low-density / |
| high-residual" tokens are dominated by non-lesion rarities (body-boundary, airβtissue |
| interfaces, vessels, motion) rather than nodules, so geometric rarity is not specific to |
| pathology. Attention, by contrast, is shaped by the SSL objective toward salient structure. |
|
|
| Per IMPLEMENTATION_SPEC Gate 1 ("If FAIL: Stop. The method reduces to generic coverage |
| regularization."): the constrained token-economy contribution rests on L(x) being lesion- |
| specific. With L(x) non-specific, the coverage floor would protect generic rare-token |
| directions, not lesions β so the headline Gate 3 claim (beating saliency on small-lesion miss |
| rate) is unlikely, and saliency is in fact the stronger localizer here. |
| |
| ## Status of the negative result |
| |
| This is a clean, publishable negative result of the kind the spec anticipates ("when does |
| coverage-constrained pruning fail, and why"): on a frozen medical SSL backbone, label-free |
| geometric lesion subspaces (density-sparse / normal-residual) do **not** localize lesions |
| competitively with attention saliency, undermining the premise that motivates a coverage floor. |
| |
| ## Options for the human (Gate 1 GO/NO-GO) |
| |
| 1. **Accept the FAIL / write up the negative result.** Spec-compliant default: stop the |
| direction here (cheapest place to die) and publish the negative finding. |
| 2. **Authorize bounded construction variants before final NO-GO** (an explicit deviation, not |
| threshold-tuning): e.g. lesion-subspace **projection-energy** score βP_L zβ instead of raw |
| density/residual; background/air-token masking before density estimation; rank/Ξ±/Ο sweep; |
| or a hybrid (residual Γ attention). These probe whether the failure is the *prior* or its |
| *operationalization*. None may touch labels (subspace stays label-free). |
| 3. **Pivot the comparison framing** to "coverage floor on the attention-defined salient set" |
| β but that abandons the label-free-geometry novelty and is effectively a different paper. |
|
|
| No further phases proceed without an explicit human decision (HALT). |
|
|